BNP Paribas Financial Markets
RGC icon

BNP Paribas Financial Markets’s Regencell Bioscience RGC Stock Holding History

BNP Paribas Financial Markets’s Portfolio RGC Stock Details RGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4,682
Closed -$72.3K – 5917
2025
Q3 		$72.3K Sell
4,682
-40,368
-90% -$579K ﹤0.01% 4437
2025
Q2 		$768K Buy
+45,050
New +$549K ﹤0.01% 3075

Other funds holding RGC

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VA
Vident Advisory Alpharetta, Georgia $11.7B AUM 37.32% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $318M AUM
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.72% 1-Year Est. Return

BNP Paribas Financial Markets's RGC Position: Q4 2025 in Review

BNP Paribas Financial Markets sold out of Regencell Bioscience (RGC) in Q4 2025, closing a stake of 4,682 shares — an estimated $72.3K sold.

BNP Paribas Financial Markets first reported a position in RGC in Q2 2025 and held it in 2 quarters. The position peaked at $768K in Q2 2025. 17 funds tracked by Wall St. Rank hold RGC as of Q4 2025.

  • BNP Paribas Financial Markets reported no remaining Regencell Bioscience position as of Q4 2025 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 4,682 Regencell Bioscience shares in Q4 2025, an estimated $72.3K.
  • BNP Paribas Financial Markets first reported a position in Regencell Bioscience in Q2 2025 and held it in 2 quarters.
  • BNP Paribas Financial Markets's Regencell Bioscience position peaked at $768K in Q2 2025.
  • 17 funds tracked by Wall St. Rank held Regencell Bioscience as of Q4 2025.

Based on BNP Paribas Financial Markets's 13F filing for Q4 2025, filed 10 Feb 2026.